Biotech Investors Eye Early-Stage Venture Vacuum
This article was originally published in Start Up
Executive Summary
Data compiled and analyzed by the Biotechnology Industry Organization and discussed at its recent CEO & Investor meeting in New York begs the question: why aren’t more new biotechs being started when investor and acquirer demand is so high?
You may also be interested in...
Biotech IPOs: High Tide
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
Venture Funding Continues Upward Climb, But On The Backs Of Fewer Investors – BIO Report
Oncology companies have been garnering the most investment from venture capital firms over the last 10 years due to their high levels of innovation, according to a new report from the industry group.
The A-List: The Trend-Shaping Series A Financings Of 2014
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.